Cargando…
Brittle Asthma: Still on Board?
(1) Background: “Brittle Asthma” was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to mode...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669403/ https://www.ncbi.nlm.nih.gov/pubmed/38002086 http://dx.doi.org/10.3390/biomedicines11113086 |
_version_ | 1785149229553942528 |
---|---|
author | Visca, Dina Ardesi, Francesco Centis, Rosella Pignatti, Patrizia Spanevello, Antonio |
author_facet | Visca, Dina Ardesi, Francesco Centis, Rosella Pignatti, Patrizia Spanevello, Antonio |
author_sort | Visca, Dina |
collection | PubMed |
description | (1) Background: “Brittle Asthma” was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to modern clinical practice, thus acquiring fresh relevance and meaning. (2) Methods: A non-systematic search of the literature was conducted using both MeSH and free-text phrases. No limitations on the research design or type of publication were applied. (3) Results: Reliable data regarding “Brittle Asthma” are lacking due to the paucity of current data and the few studies available. After a few years of reworking, it was divided into two sub-classes: one characterized by a wide PEF variability despite high-dose therapy and the other by sudden acute attacks in otherwise apparently normal airway functions or well-controlled asthma. Their characteristics were hardly defined because of their low prevalence. Data regarding risk factors, atopy, mechanisms, and treatments were analyzed. (4) Conclusions: Over time, different terminology has been introduced to define asthma severity and control. It would be worth investigating whether the term “Brittle Asthma” previously used may be helpful to find new hints to stratify patients and improve disease management. |
format | Online Article Text |
id | pubmed-10669403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106694032023-11-17 Brittle Asthma: Still on Board? Visca, Dina Ardesi, Francesco Centis, Rosella Pignatti, Patrizia Spanevello, Antonio Biomedicines Review (1) Background: “Brittle Asthma” was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to modern clinical practice, thus acquiring fresh relevance and meaning. (2) Methods: A non-systematic search of the literature was conducted using both MeSH and free-text phrases. No limitations on the research design or type of publication were applied. (3) Results: Reliable data regarding “Brittle Asthma” are lacking due to the paucity of current data and the few studies available. After a few years of reworking, it was divided into two sub-classes: one characterized by a wide PEF variability despite high-dose therapy and the other by sudden acute attacks in otherwise apparently normal airway functions or well-controlled asthma. Their characteristics were hardly defined because of their low prevalence. Data regarding risk factors, atopy, mechanisms, and treatments were analyzed. (4) Conclusions: Over time, different terminology has been introduced to define asthma severity and control. It would be worth investigating whether the term “Brittle Asthma” previously used may be helpful to find new hints to stratify patients and improve disease management. MDPI 2023-11-17 /pmc/articles/PMC10669403/ /pubmed/38002086 http://dx.doi.org/10.3390/biomedicines11113086 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Visca, Dina Ardesi, Francesco Centis, Rosella Pignatti, Patrizia Spanevello, Antonio Brittle Asthma: Still on Board? |
title | Brittle Asthma: Still on Board? |
title_full | Brittle Asthma: Still on Board? |
title_fullStr | Brittle Asthma: Still on Board? |
title_full_unstemmed | Brittle Asthma: Still on Board? |
title_short | Brittle Asthma: Still on Board? |
title_sort | brittle asthma: still on board? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669403/ https://www.ncbi.nlm.nih.gov/pubmed/38002086 http://dx.doi.org/10.3390/biomedicines11113086 |
work_keys_str_mv | AT viscadina brittleasthmastillonboard AT ardesifrancesco brittleasthmastillonboard AT centisrosella brittleasthmastillonboard AT pignattipatrizia brittleasthmastillonboard AT spanevelloantonio brittleasthmastillonboard |